title: [An analysis of efficacy and related factors of itraconazole in the treatment of invasive fungal infection in hematological diseases].
abstract: OBJECTIVE
  To investigate the effects and related factors of itraconazole in the treatment of invasive fungal infection (IFI) in the patients with blood diseases (BD).
  
  
  METHODS
  A total of 156 BD patients with IFI treated with itraconazole in General Hospital, Tianjin Medical University from 2005 to 2008, were retrospectively analyzed.
  
  
  RESULTS
  Of these patients, 92 were with underlying malignant BD, and 64 with non-malignant BD; 77 possible IFI, and others proven IFI. A total of 94 (63.5%) patients were responded to itraconazole successfully, while 54 (36.5%) failed. The underlying malignant BD, post-chemotherapy, neutrophil count less than 0.5×10(9)/L, positive fungus culture, and bacteria infection were related with the response to itraconazole significantly, while patient's age, application of other antibiotics, positive G test, IFI localization, haemoglobin level and platelet counts were not. Five patients was changed other anti-IFI therapy because of side effects, including gastrointestinal ill (3 cases with nausea or vomiting) and tachycardia (2 cases).
  
  
  CONCLUSIONS
  Itraconazole was effective and safe in the treatment of IFI in the patients with BD. Underlying malignant BD, agranulocytosis, bacteria infection, and delayed anti-IFI therapy might reduce itraconazole therapeutic effects.
authors.affiliation: Hematology Department, General Hospital, Tianjin Medical University, Tianjin 300052, China.
authors.forename: Chun-yan
authors.initials: CY
authors.lastname: Liu
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Wu
authors.forename: Er-bao
authors.initials: EB
authors.lastname: Ruan
authors.forename: Wen
authors.initials: W
authors.lastname: Qu
authors.forename: Guo-jin
authors.initials: GJ
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Liang
authors.forename: Xiao-ming
authors.initials: XM
authors.lastname: Wang
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Jia
authors.initials: J
authors.lastname: Song
authors.forename: Jing
authors.initials: J
authors.lastname: Guan
authors.forename: Hua-quan
authors.initials: HQ
authors.lastname: Wang
authors.forename: Li-min
authors.initials: LM
authors.lastname: Xing
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Zong-hong
authors.initials: ZH
authors.lastname: Shao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006402:Hematologic Diseases / Q000382:microbiology*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole